APL-2 LONG-TERM SAFETY AND EFFICACY EXTENSION STUDY
- Conditions
- -D595 Paroxysmal nocturnal haemoglobinuria [Marchiafava-Micheli]Paroxysmal nocturnal haemoglobinuria [Marchiafava-Micheli]D595
- Registration Number
- PER-037-20
- Lead Sponsor
- Apellis Pharmaceuticals Inc.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
1.Subjects with PNH who have participated in an APL-2 clinical trial. Subjects who received treatment with APL-2
must have experienced clinical benefit in the opinion of the Investigator.
2.Willing and able to give written informed consent
3.Women of child-bearing potential (WOCBP) must have a negative pregnancy test and must agree to continue to use an approved method of contraception for the duration of the study and 60 days after their last dose of study drug.
4.Males must agree to continue to use an approved method of contraception and must agree to refrain from donating sperm for the duration of the study and 60 days after their last dose of study drug.
1.Subjects who have withdrawn from an APL-2 clinical study.
2.Any condition that could increase the subject’s risk by participating in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.